Last week Verastem presented additional Copiktra data at the Leerinks Health Care Conference followed by a Q&A session by analysts. The webcast can be accessed here. In this article, I discuss the … [Read more...] about Can Verastem Shake the DownTrend?
Lymphoma Patients Want and Need A Better Quality Of Life As a Lymphoma survivor, I can say unequivocally, that TO MUCH TIME is spent in the chemo wing, away from our families. Therefore, as … [Read more...] about (Nasdaq: VSTM) Verastem, Better Quality of Life? A Patients Perspective
Overview Wednesday October 24th, 2018 the stock market was slashed across the board with the DOW erasing all its gains for the year and dripping red. The Nasdaq was hit with equal force. Comments from … [Read more...] about Potentially Lucrative Opportunities Amidst A Stock Market Bloodbath
For months Verastem Oncology (VSTM) investors have been eagerly awaiting the FDA's decision on it's lead product Duvelisib; a PI3K-δ (delta) and PI3K-γ (gamma) inhibitor that was granted Orphan Drug … [Read more...] about VSTM Overaction to Black Box Label Creates Buying Opportunity
Today September 20th Galectin Therapeutics (NASDAQ: GALT) announced promising results from their phase 1b clinical trial of GR-MD-02 and KEYTRUDA® in Advanced Melanoma and Expansion of the Trial. … [Read more...] about Market Hasn’t Grasped the Magnitude of GALT Phase1b Keytruda Combo Study